J. Goldman & Co’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

J. Goldman & Co’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.3M	Sell	167,100 -133,000	-44%	-$16.6M	0.62%	30
2025 Q4	$36.6M	Buy	300,100 +266,600	+796%	+$30.6M	0.96%	17
2025 Q3	$3.36M	Sell	33,500 -16,500	-33%	-$1.49M	0.08%	237
2025 Q2	$4.15M	Sell	50,000 -55,200	-52%	-$4.4M	0.1%	216
2025 Q1	$8.53M	Buy	105,200 +37,600	+56%	+$3.36M	0.21%	144
2024 Q4	$6.09M	Buy	+67,600	New	+$6.55M	0.16%	181
2024 Q1	–	Sell	-130,000	Closed	-$11.6M	–	538
2023 Q4	$11.6M	Sell	130,000 -18,500	-12%	-$1.37M	0.47%	67
2023 Q3	$10.8M	Buy	+148,500	New	+$11.9M	0.38%	83
2023 Q2	–	Sell	-81,000	Closed	-$6.17M	–	507
2023 Q1	$6.17M	Buy	81,000 +61,000	+305%	+$5.06M	0.25%	118
2022 Q4	$1.66M	Sell	20,000 -20,500	-51%	-$1.66M	0.08%	190
2022 Q3	$3.21M	Buy	+40,500	New	+$3.41M	0.15%	162
2021 Q4	–	Sell	-81,000	Closed	-$10.2M	–	451
2021 Q3	$10.2M	Buy	81,000 +6,000	+8%	+$773K	0.51%	51
2021 Q2	$10.2M	Buy	75,000 +21,000	+39%	+$2.76M	0.39%	66
2021 Q1	$7.33M	Sell	54,000 -18,000	-25%	-$2.69M	0.24%	109
2020 Q4	$10.1M	Buy	72,000 +15,800	+28%	+$2.02M	0.51%	52
2020 Q3	$6.26M	Buy	+56,200	New	+$6.3M	0.42%	76
2020 Q1	–	Sell	-70,000	Closed	-$6.66M	–	347
2019 Q4	$6.66M	Sell	70,000 -96,500	-58%	-$8.35M	0.48%	59
2019 Q3	$12.7M	Buy	+166,500	New	+$13.8M	0.95%	28
2019 Q2	–	Sell	-65,000	Closed	-$5.88M	–	355
2019 Q1	$5.88M	Hold	65,000	–	–	0.33%	92
2018 Q4	$4.66M	Buy	+65,000	New	+$5.24M	0.36%	85
2018 Q3	–	Sell	-30,000	Closed	-$2.86M	–	410
2018 Q2	$2.86M	Sell	30,000 -128,000	-81%	-$11.8M	0.15%	179
2018 Q1	$13.9M	Buy	+158,000	New	+$14.4M	0.59%	36
2017 Q4	–	Sell	-60,000	Closed	-$5.19M	–	450
2017 Q3	$5.19M	Buy	+60,000	New	+$4.81M	0.26%	111
2017 Q2	–	Sell	-219,000	Closed	-$15.2M	–	423
2017 Q1	$15.2M	Buy	219,000 +180,000	+462%	+$12.1M	0.75%	28
2016 Q4	$2.31M	Sell	39,000 -216,000	-85%	-$13.3M	0.15%	165
2016 Q3	$16.9M	Buy	255,000 +190,000	+292%	+$11.8M	0.95%	18
2016 Q2	$3.52M	Sell	65,000 -110,000	-63%	-$6.03M	0.18%	130
2016 Q1	$9.04M	Buy	175,000 +95,000	+119%	+$4.93M	0.56%	48
2015 Q4	$5.62M	Sell	80,000 -116,000	-59%	-$7.91M	0.58%	59
2015 Q3	$12.2M	Sell	196,000 -51,500	-21%	-$4.06M	1.05%	19
2015 Q2	$20.8M	Sell	247,500 -22,500	-8%	-$1.75M	1.26%	10
2015 Q1	$20.3M	Buy	+270,000	New	+$18.9M	1.26%	11
2014 Q4	–	Sell	-45,000	Closed	-$2.34M	–	288
2014 Q3	$2.34M	Buy	45,000 +22,500	+100%	+$1.15M	0.14%	168
2014 Q2	$1.16M	Sell	22,500 -82,500	-79%	-$3.72M	0.08%	178
2014 Q1	$4.99M	Buy	+105,000	New	+$5.37M	0.37%	89

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

J. Goldman & Co's XBI Position: Q1 2026 in Review

J. Goldman & Co opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q1 2026: 2,000 shares worth $255K. The stake represents 0.01% of the portfolio and ranks #580 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in XBI as recently as Q4 2024.

J. Goldman & Co first reported a position in XBI in Q4 2017 and has held it in 8 quarters since. The position peaked at $1.52M in Q4 2024. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

J. Goldman & Co held 2,000 shares of State Street SPDR S&P Biotech ETF worth $255K as of Q1 2026.
State Street SPDR S&P Biotech ETF was a new J. Goldman & Co position in Q1 2026.
State Street SPDR S&P Biotech ETF made up 0.01% of J. Goldman & Co's portfolio in Q1 2026, its #580 holding.
J. Goldman & Co first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and has held it in 8 quarters since.
J. Goldman & Co's State Street SPDR S&P Biotech ETF position peaked at $1.52M in Q4 2024.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.